Annual Report 2008


Click Here to Download

Stock Exchange Announcements

Positive outcome reached at 16 weeks for Avexa's ATC phase III trial

Update to 2009 capital raising effort

Avexa signs option agreement with Tibotec

Rights Issue completed - $17m raised

All Other Announcements

Latest Company Presentations/Reports

ABN AMRO Research Report May 2009

Company Presentation April 2009

ABN AMRO Research Report Feb 2009

AGM CEO Presentation November 2008

Avexa
  • Home
  • Corporate
    • Company Overview
    • Business Development
    • People
    • Corporate Governance
    • Avexa Employee Share Option Plan
  • Projects
    • HCV
    • HIV
    • Scientific Collaborations
    • VRI
  • Clinical Trials
    • AVX 101 and AVX 102 Posters
    • AVX-201 Trial
  • News
    • Press Releases 2009
    • Press Releases 2008
    • Press Releases 2007
    • Press Releases 2006
    • Press Releases 2005
  • Investor Relations
    • AGM
    • Company Reports
    • Prospectus 2007
    • Shareholder Newsletters
    • Analyst Reports
  • Presentations
    • Company Presentation April 2009
    • HIV Glasgow Conference November 2008 Apricitabine Oral Presentation
    • HIV Glasgow Conference November 2008 Apricitabine Poster
    • ICAAC Poster Washington 2008
    • AGM CEO Presentation November 2008
    • Poster XV11 HIV Drug Resistance Workshop June 2008
    • Investor Presentation March 2008
    • BIO CEO Investor Conference New York February 2008
    • CROI Poster Boston 2008
    • CEO Presentation AGM 2007
    • Investor Presentation October 2007
    • Investor Roadshow Presentation 2007
    • Investor Roadshow Presentation March 2007
    • HIV Glasgow Conference November 2006 Apricitabine Poster
    • AGM CEO presentation 2006
    • Investor Roadshow Presentation November 2006
  • FAQs
    • Avexa Demerger
    • General
    • Annual Report Information
    • Shareholder Information
  • Contact Us
    • Contact Form
    • Careers
Search     Site Map
Terms and Conditions |  Privacy Statement |  © 2008 Avexa Limited All Rights Reserved